ATE290595T1 - Gamma-heregulin - Google Patents

Gamma-heregulin

Info

Publication number
ATE290595T1
ATE290595T1 AT97934059T AT97934059T ATE290595T1 AT E290595 T1 ATE290595 T1 AT E290595T1 AT 97934059 T AT97934059 T AT 97934059T AT 97934059 T AT97934059 T AT 97934059T AT E290595 T1 ATE290595 T1 AT E290595T1
Authority
AT
Austria
Prior art keywords
adhesins
chimeric
erbb2
heteromultimer
heteromultimeric
Prior art date
Application number
AT97934059T
Other languages
English (en)
Inventor
Gabriele M Schaefer
Mark Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE290595T1 publication Critical patent/ATE290595T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/971—Capture of complex after antigen-antibody reaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97934059T 1996-07-12 1997-07-08 Gamma-heregulin ATE290595T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
PCT/US1997/011841 WO1998002541A1 (en) 1996-07-12 1997-07-08 Gamma-heregulin

Publications (1)

Publication Number Publication Date
ATE290595T1 true ATE290595T1 (de) 2005-03-15

Family

ID=21805329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934059T ATE290595T1 (de) 1996-07-12 1997-07-08 Gamma-heregulin

Country Status (8)

Country Link
US (6) US6096873A (de)
JP (2) JP4382879B2 (de)
AT (1) ATE290595T1 (de)
AU (1) AU727606B2 (de)
CA (1) CA2257839C (de)
DE (1) DE69732711T2 (de)
IL (4) IL127892A0 (de)
WO (1) WO1998002541A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
ATE290595T1 (de) 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
WO2000035474A1 (en) * 1998-12-11 2000-06-22 Khurana Tejvir S Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DE60033658T2 (de) * 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
EP2110138A1 (de) 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002055704A2 (en) * 2001-01-09 2002-07-18 Curagen Corp Proteins, polynucleotides encoding them and methods of using the same
DE60231833D1 (de) * 2001-07-31 2009-05-14 Univ Wayne State Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1572972A4 (de) * 2002-11-21 2007-11-21 Genentech Inc Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
DE60323876D1 (de) * 2002-12-17 2008-11-13 Centre Nat Rech Scient Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型her3と免疫反応性の改善された抗体
KR101186218B1 (ko) * 2009-08-21 2012-10-08 경희대학교 산학협력단 히레귤린 베타1의 egf-성 도메인 펩타이드의 용도
AU2010306777C1 (en) * 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE68929402T2 (de) 1988-12-22 2002-12-05 Genentech, Inc. Verfahren zur herstellung von wasserlöslichen polypeptiden
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0739904A1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische Reagenzien für die AIDS-Therapie
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
KR920018078A (ko) * 1991-03-17 1992-10-21 예다 리서치 앤드 디벨롭먼트 캄패니 리미티드 neu수용체 자극 인자 및 그의 제조방법과 그를 이용하여 세포의 증식 및 분화를 조절하는 방법
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU3665893A (en) * 1992-02-12 1993-09-03 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
WO1994008007A1 (en) * 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
AU7042994A (en) * 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
CN1111910A (zh) * 1993-07-06 1995-11-15 霍夫曼-拉罗奇有限公司 乳腺调节素,非激素依赖性乳腺癌细胞特异蛋白
JP3442784B2 (ja) 1993-11-23 2003-09-02 ジェネンテク,インコーポレイテッド キナーゼ受容体活性化検定法
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin

Also Published As

Publication number Publication date
IL191078A0 (en) 2008-11-03
US6500941B1 (en) 2002-12-31
US6916624B2 (en) 2005-07-12
IL191078A (en) 2011-12-29
JP4382879B2 (ja) 2009-12-16
AU3720897A (en) 1998-02-09
DE69732711T2 (de) 2006-03-16
US8226935B2 (en) 2012-07-24
CA2257839A1 (en) 1998-01-22
IL191077A (en) 2011-12-29
JP2000515740A (ja) 2000-11-28
US20030078389A1 (en) 2003-04-24
DE69732711D1 (de) 2005-04-14
US20100135957A1 (en) 2010-06-03
US20060029602A1 (en) 2006-02-09
CA2257839C (en) 2012-10-23
US20090042797A1 (en) 2009-02-12
US7585673B2 (en) 2009-09-08
US6096873A (en) 2000-08-01
IL191077A0 (en) 2008-11-03
AU727606B2 (en) 2000-12-14
IL127892A0 (en) 1999-10-28
JP2009235108A (ja) 2009-10-15
WO1998002541A1 (en) 1998-01-22
IL127892A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
DE69732711D1 (de) Gamma-heregulin
ATE486937T1 (de) Chimärische heteromultimerische adhesine
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
NZ516258A (en) Tek antagonists
PT915974E (pt) Ligandos de receptores de tie-2 modificados
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE69129990D1 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
DK2067790T3 (da) Agonistantistof mod proteintyrosinkinase SAL-S1
MA32449B1 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
ATE412432T1 (de) Internalisierende erbb2 antikörper
EP0584082A4 (en) Domains of extracellular region of human platelet derived growth factor receptor polypeptides
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
GB9406857D0 (en) Improvements in or relating to organic compounds
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
AU5588094A (en) The pct-65 serotonin receptor
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
EP1456239A4 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties